ViaCyte hauls in $5.4M for diabetes drug; Eisai's cancer drug flunks a Phase III;

@FierceBiotech: EuroBiotech report: Roche commits to Danish RNA lab, £3B London incubator hits go, Biotechs in post-IPO slump. Report | Follow @FierceBiotech

@JohnCFierce: Interesting fact, when DoD stopped $SRPT's work on Ebola, they left in a provision to reactivate the $291M contract. Story | Follow @JohnCFierce

@DamianFierce: Auris Medical prices $56M IPO, ushers in the era of $EARS on Wall Street. Release (PDF) | Follow @DamianFierce

> ViaCyte raised $5.4 million in Series C cash to support its work on VC-01, a cell therapy treatment for diabetes. News

> Eisai's eribulin failed to meet its primary endpoint of overall survival in a Phase III trial on patients with non-small cell lung cancer. Story (PDF)

> Nicox has exercised its right co-market latanoprostene bunod, a Bausch + Lomb-partnered treatment for glaucoma and ocular hypertension. More

Medical Device News

@FierceMedDev: Physicians hesitate to use HeartMate II pump after NEJM study, Thoratec down 30%. Story | Follow @FierceMedDev

@StacyALawrence: ICYMI: Scientist robot gets venture funding from Omega. Item | Follow @StacyALawrence

@VarunSaxena2: Elizabeth Pritts says her study's estimate of uterine sarcoma in morcellator patients will be 1:7450 morcellation. More | Follow @VarunSaxena2

@MichaelGFierce: Carnegie Mellon team creates self-assembling nanofibers for shaped delivery vehicles. More | Follow @MichaelGFierce

@EmilyWFierce: Boston Scientific subpoenaed by federal investigators over cardiology devices start-up. MassDevice story | Follow @EmilyWFierce

> Medtronic and Covidien face FTC pushback for pending merger. News

> GE-funded NGO aims to repair developed-world medical devices in the developing world. More

> Four unanswered questions about the looming LDT regulations. Item

Pharma News

@FiercePharma: Top in FierceVaccines Thursday: Sanofi dengue vaccine filings could come as soon as next year's Q1, CEO says. Article | Follow @FiercePharma

@EricPFierce: Instead of buying counterfeit Viagra from China, this guy bought APIs and whipped up an ED drug in his home lab. Green Bay Press Gazette story | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. Like it? Subscribe here free. | Follow @CarlyHFierce

> Pfizer faces growing legal threat over Lipitor. News

> NICE raises ire of breast cancer patients with rejection of Roche's Kadcyla. Article

> Novartis can't convince judge to free it from kickbacks case. More

Suggested Articles

Former Ipsen and Novartis exec Harout Semerjian has been tapped as the latest chief executive of troubled Immunomedics.

A COVID-19 vaccine developed by a Mass General spinoff is among the candidates emerging from partnerships between tech developers and bio researchers.

Vir and GlaxoSmithKline will pool their resources to develop vaccines and treatments for coronaviruses, starting with two antibodies against COVID-19.